Dear Colleague,

To support vaccine research and development, The Native Antigen Company is thrilled to introduce our newly developed Southern Hemisphere Haemagglutinin (HA) and Neuraminidase (NA) antigens! These antigens have been designed in accordance with the WHO-recommended egg-based and recombinant vaccine seasonal strains.

Expressed from our proprietary VirtuE™ HEK293 expression system, these antigens exhibit proper glycosylation and folding.

As of the 2022-23 winter season, we have offered our Haemagglutinin proteins as stabilized trimers, essential for the study of neutralizing antibodies in vaccine development. Since the 2023-24 winter season, our Neuraminidase proteins presented using an N-terminal domain, which generates stable and enzymatically active NA tetramers. In its native tetrameric conformation, neuraminidase protein generates high levels of NA-reactive binding and inhibition antibodies (Deng et al., 2021).

We are keen to undertake the production of novel strains/mutants of Influenza HA & NA as a bespoke service, including in-vivo biotinylated antigens. Order your Southern Hemisphere Seasonal Influenza Antigens today by clicking the button below.